GLP-1 medicines can be helpful tools for the treatment of obesity and for other important health goals, but they’re not for everyone. Here are common reasons they may not be the right choice for you.

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

Squibb announced that the U.S. Food and Drug Administration has updated the U.S. Prescribing Information for Camzyos, ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...

Trump said he wants to bring more drug manufacturing to the U.S. At a political fundraising dinner on Tuesday night, President Donald Trump said he plans to announce tariffs on pharmaceuticals soon.

Mr Johnson began noticing a series of unsettling side effects. Tech entrepreneur Bryan Johnson, dubbed the "anti-ageing millionaire" in a YouTube video revealed that a major miscalculation ...

BALTIMORE (WBFF) — Officials from Baltimore along with Drug Enforcement Agency (DEA) members announced the "takedown" of a drug trafficking organization that was connected to violence and ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs ...

Federal parties have pitched different approaches to dealing with the toxic drug crisis in B.C. — particularly when it comes to overdose prevention and supervised consumption sites.